170 POSTER

NMS-E628, a potent and orally available small molecule inhibitor of anaplastic lymphoma kinase, reduces tumor growth in an intracranial model of ALK-dependent NSCLC

E. Ardini[1], M. Menichincheri[2], P. Magnaghi[1], C. De Ponti[1], N. Amboldi[1], A. Degrassi[3], M. Russo[3], P. Orsini[2], E. Pesenti[3], A. Galvani[1]. [1]*Nerviano Medical Sciences Srl, Cell Biology, Nerviano (Milano), Italy;* [2]*Nerviano Medical Sciences Srl, Medicinal Chemistry, Nerviano (Milano), Italy;* [3]*Nerviano Medical Sciences Srl, Pharmacology, Nerviano (Milano), Italy*

The ALK tyrosine kinase gene undergoes chromosomal rearrangements in the majority of Anaplastic Large Cell Lymphoma (ALCL) cases, and in a subset of Non Small Cell Lung Cancer (NSCLC), giving rise to various fusion proteins which bear a constitutively activated ALK kinase domain. Additionally, full length ALK is often found to be activated by gene amplification or by kinase domain point mutations in a significant fraction of neuroblastomas. In all three of these tumor types, there is strong evidence that activated ALK kinase is a driver oncogene, and that pharmacological intervention with small molecule inhibitors which target this kinase represents a promising therapeutic approach for affected patient populations.

We have previously presented the identification of NMS-E628, an orally available small-molecule ALK kinase inhibitor. Here, we describe further preclinical characterization of this molecule. In vitro, NMS-E628 very selectively inhibited proliferation of ALK-dependent cell lines with IC50s in the sub 100 nM range. Interestingly, short-term exposure of the Karpas-299 ALK+ ALCL cell lines to NMS-E628 induced long lasting and profound induction of cell cycle block and inhibition of proliferation which was maintained for several days following withdrawal of the drug. Concomitant with this effect, sustained inhibition of NPM-ALK autophosphorylation and downstream signaling was observed, despite persistent expression of NPM-ALK fusion protein.

In a murine subcutaneous xenograft model employing the H2228 human ALK+ NSCLC line, activity of NMS-E628 compared favorably with that of PF-02341066 (Crizotinib®), an agent which demonstrated a 57% response rate in ALK+ NSCLC patients in phase II clinical studies. Oral administration of NMS-E628 to H2228 tumor bearing mice yielded complete and durable regressions in all treated animals.

Since NMS-E628 is able to pass the blood–brain barrier, the compound was also tested for efficacy in an intracranial xenograft model employing H2228 tumors. MRI imaging demonstrated that NMS-E628 was able to effectively and dose-dependently control the growth of these intracranial tumors, leading to increased survival.

171 POSTER

Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with etoposide (VP-16) in small cell lung cancer (SCLC) cell lines and xenografts

P. Taverna[1], L. Huang[1], G.S. Choy[2], M. Azab[2]. [1]*SuperGen Inc., Translational Pharmacology, Dublin, USA;* [2]*SuperGen Inc., Clinical Development, Dublin, USA*

Background: MP-470 is an orally bioavailable multi-targeted tyrosine kinase inhibitor specifically designed to be a potent inhibitor of mutant c-Kit and PDGFRα. MP-470 also decreases Rad51-mediated homologous recombination DNA repair and increases cancer cells' chemosensitivity (Bristow et al., 2009). In a Phase 1b clinical study of MP-470 in combination with VP16+Carboplatin, several responses were observed in previously treated SCLC. To support a potential Phase 2 clinical study, we evaluated the effects of MP-470 as single agent and in combination with VP-16 and carboplatin in a panel of 5 SCLC cell lines. Efficacy of MP-470+VP-16 combination was studied also in SCLC NCI-H146 xenografts.

Methods: Viability of 5 SCLC cell lines (LB12-SCLC/OC2, LB13-SCLC/OC3, NCI-H146, NCI-H69 and NCI-H82) after treatment with MP-470, VP-16 and carboplatin as single agents or in combination was evaluated using the MTS assay and combination index (CI) was determined after simultaneous treatment for 72 hrs. Modulation of cell signaling pathways after MP-470 treatment was evaluated in these SCLC cell lines and xenografts by Reverse Phase Protein Array (RPPA) and Western blot. Tumor growth inhibition after administration of MP-470 and VP-16 was evaluated in NCI-H146 xenografts established in Swiss nude mice.

Results: All 5 SCLC cell lines tested were sensitive to MP-470 with LB12-SCLC/OC2 being the most sensitive (4.79 μM). When MP-470 and VP-16 were combined, effects produced were generally additive (on three of the five cell lines tested); synergism was observed in NCI-H146 (CI = 0.68±0.18). When MP-470 and VP-16 were combined to carboplatin, significant synergism was again evident in NCI-H146 (CI = 0.72±0.12) and additivity was observed in NCI-H69 and LB12-SCLC/OC2. RPPA analysis of cell extracts showed a significant dose and time dependent modulation of phospho-S6 and phospho-4EBP1 after MP-470 treatment. In vivo PO administration of MP-470 in combination with IV VP-16 in NCI-H146 tumor-bearing mice at well tolerated doses and regimens produced a sustained reduction in T/C ratio <39%. Modulation of Akt and 4EBP1 phosphorylation was observed in tumor extracts prepared from NCI-H146 xenografts after treatment with MP-470.

Conclusions: Overall, MP-470 is synergistic with DNA-damaging agents like VP-16 and improves VP-16 anti-cancer activity in SCLC xenografts. MP-470 warrants further testing in pre-clinical and clinical studies in combination with VP16-containing chemotherapy.

172 POSTER

Molecular mechanisms of the combination treatment of cetuximab and dasatinib in Kras mutant colorectal tumors

E.F. Dunn[1], M. Iida[1], R.A. Myers[1], C. Li[1], D.L. Wheeler[1]. [1]*University of Wisconsin, Human Oncology, Madison, USA*

Kras mutation is a predictive biomarker for resistance to cetuximab (Erbitux®) in metastatic colorectal cancer (mCRC). This study sought to determine if Kras mutant CRC lines could be sensitized to cetuximab *in vivo* using the FDA approved Src family kinase (SFK) inhibitor, dasatinib (BMS-354825, sprycel®). We analyzed 16 CRC lines for: (1) Kras mutation status, (2) dependence on mutant Kras signaling, (3) expression level of EGFR and SFKs. From these analyses, we selected three Kras mutant (LS180, LoVo, and HCT116) cell lines, and two Kras wild type cell lines (SW48 and CaCo2). *In vitro*, using PDL/laminin plates, Kras mutant cell lines were resistant to cetuximab whereas parental controls showed sensitive to cetuximab. Treatment with cetuximab and dasatinib showed a greater anti-proliferative effect on Kras mutant line as compared to either agent alone. To investigate a mechanism for this increased response in the combinatorial therapy we performed Human Phospho-kinase Antibody Array analysis (ARY003, R&D systems) measuring the relative phosphorylation levels of phosphorylation of 46 intracellular serine/threonine/tyrosine kinases in untreated, cetuximab, dasatinib or the combinatorial treatment in LS180, LoVo and HCT116 cells. The results of this experiment showed a compelling decrease in a broad spectrum of kinases when compared to the untreated or monotherapy treated controls. To strengthen our *in vitro* findings we analyzed tumor growth delay with cetuximab, dasatinib or the combination *in vivo*. Kras mutant xenografts showed resistance to cetuximab therapy, whereas Kras wild type demonstrated an anti-tumor response when treated with cetuximab. Kras mutant tumors exhibited minimal response to dasatinib in monotherapy. However, *as in vitro*, Kras mutant lines exhibited a response to the combination of cetuximab and dasatinib as compared to controls. Combinatorial treatment of Kras mutant xenografts resulted in decreased cell proliferation as measured by Ki67 and higher rates of apoptosis as measured by TUNEL compared to controls. The data presented herein indicate that dasatinib can sensitize Kras mutant CRC tumors to cetuximab and may do so by altering the activity of several key kinases. Further, these results suggest that signaling via the EGFR and SFKs may be necessary for cell proliferation and survival of Kras mutant CRC tumors. This data strengthen the rationale for clinical trials in this genetic setting combining cetuximab and dasatinib.

173 POSTER

Synergistic toxicity of tyrosine kinase inhibitors with Hsp90 inhibitor 17-AAG in lung cancer cell line

V.L. Damaraju[1], M. Wilson[1], M. Kuzma[1], D. Mowles[1], C.E. Cass[1], M.B. Sawyer[1]. [1]*Cross Cancer Institute-Alberta Health Services-Cancer care, Oncology, Edmonton AB, Canada*

Background: 17-allylamino demethoxygeldanamycin (17-AAG), a Hsp90 inhibitor is a synthetic derivative of geldanamycin which exhibits 100-fold higher binding affinity for tumor-cell derived Hsp90 compared to normal cells. 17-AAG blocks oncogene switching and inhibits multiple signaling pathways including ErbB and Src kinases. Gefitinib was shown to lose its ability to modulate ErbB pathways due to oncogene switching. Since 17-AAG blocks this oncogene switching, we examined effects of combining 17-AAG with tyrosine kinase inhibitors (TKIs) such as erlotinib (EGFR selective with no effect on A549 cells), gefitinib (EGFR selective), vandetanib (EGFR and VEGFR selective) and lapatinib (EGFR and Her-2 selective) in a lung cancer cell line A549. In addition we studied effects of 17-AAG on human nucleoside transporters because antagonistic effects of combination of 17-AAG with cytarabine were reported earlier in leukemic cells.

Materials and Methods: The human lung cancer cell line A549 was obtained from American Type Culture Collection (Manassas,VA). Cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 10% glucose. All cultures were kept at 37ºC in 5% CO_2/95% air and sub-cultured every 2−3 days to